Alpha Tau Doses First Immunocompromised Patient in ADMIRE cSCC Study

summarizeSummary

Alpha Tau has treated the first immunocompromised patient in its ADMIRE study for recurrent cSCC, extending Alpha DaRT into a high-risk population with limited alternatives.

check_boxKey Events · Product Development and Regulatory · DRTS

• First Patient Dosed in ADMIRE Study

  At Banner MD Anderson Cancer Center, the first immunocompromised patient with recurrent cSCC has been successfully treated with Alpha DaRT, signaling the launch of the ADMIRE study.

• Expands Addressable Population

  ADMIRE focuses on immunocompromised patients — a group with a 65- to 100-fold higher incidence of cSCC and limited treatment options, partly because checkpoint inhibitors carry risks like organ rejection.

• Study Design and Endpoints

  The company-sponsored, multicenter study is designed to enroll up to 28 patients at up to 8 U.S. sites, with objective response rate (ORR) per RECIST v1.1 as the primary endpoint.

• Builds on ReSTART Momentum

  This milestone follows the recent completion of enrollment in the ReSTART pivotal trial for recurrent cSCC, where the same clinical team gained experience with Alpha DaRT.

auto_awesomeAnalysis · DRTS · Industrial Applications And Services

Dosing has begun in the ADMIRE study, marking Alpha Tau's expansion of Alpha DaRT into immunocompromised patients with recurrent cutaneous squamous cell carcinoma — a population facing a 65- to 100-fold higher cancer risk and few treatment options. This milestone builds on the recently completed enrollment in the ReSTART pivotal trial and broadens the therapy's addressable market. The company-sponsored study plans to enroll up to 28 patients across 8 U.S. sites, with objective response rate as the primary endpoint.